MedTrace Logo

Estrogen Therapy in Non-severe COVID-19 Patients

NCT04539626 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-04-05

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the effect of additional estradiol estrogen therapy on clinical response and mortality in non-severe COVID-19 patients

Conditions

Interventions

DRUG

Estrogen Therapy

EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)

Sponsors & Collaborators

  • CMN "20 de Noviembre"

    lead OTHER

Principal Investigators

  • Rodrigo Ruz Barros, MD · CMN "20 de Noviembre"

  • Daniel Santillán Cortés, MSc · CMN "20 de Noviembre"

  • Mónica Escamilla Tilch, PhD · CMN "20 de Noviembre"

  • Juan A Pineda Juárez, PhD · CMN "20 de Noviembre"

  • Sandra Muñoz López, MD · CMN "20 de Noviembre"

  • Maricela Escarela Serrano, MD · CMN "20 de Noviembre"

  • Paul Mondragón Terán, PhD · CMN "20 de Noviembre"

  • Alberto H De la Vega Bravo, MD · CMN "20 de Noviembre"

  • Alfredo L Cortés Algara, MD, MSc · CMN "20 de Noviembre"

  • Samuel Reyes-Long, MSc · Neurociencias básicas, Instituto Nacional de Rehabilitación LGII

  • Cindy Bandala, MD MSc PhD · Neurociencias básicas, Instituto Nacional de Rehabilitación LGII; Escuela Superior de Medicina, Instituto Politécnico Nacional

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2023-04-03
Completion
2023-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539626 on ClinicalTrials.gov